119th General Meeting of the KCS

Type Oral Presentation
Area Oral Presentation of Young Analytical Chemists Ⅰ
Room No. 303호
Time THU 09:44-:
Code ANAL1.O-15
Subject Circulating Biomarker Database (CBD), A Comprehensive Transition Database for LC-MS/MS Based Screening for FDA-approved Biomarkers in Blood
Authors 김두영, 김민식*
경희대학교 응용화학과, Korea
Abstract Biomarkers are a type of biological molecules that are objective indications of medical state which can be measured accurately and reproducibly.[1] Currently, there are thousands of biomarker tests approved by FDA and only a few are being measured when a clinical concern is raised by medical doctors. Although the early diagnosis can be done by monitoring them regularly, there is no FDA-approved method to carry out the routine measurement of these biomarkers in a global fashion. Recent advance in high resolution mass spectrometry can now allow a clinical laboratory to measure analytes of interest from specimen very accurately and reproducibly.[2] Especially, the targeted mass spectrometry such as MRM (multiple reaction monitoring) has the potential to be the major technology to monitor these thousands of biomarkers in a clinical setting. In this regards, we create a database called Circulating Biomarker Database (CBD) as the first step which is a comprehensive transition list for LC-MS/MS-based screening of FDA-approved biomarkers. In this database, precursor ions of 583 biomarkers and their fragment ions as transitions are listed together towards a comprehensive monitoring method to screen most biomarkers in blood. In conclusion, Circulating Biomarker Database can be used for clinical diagnostics and prognostics in the future medicine.
E-mail dykim1028@naver.com